1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cantargia AB

Cantargia AB

1.37
SEK
+0.01
(+0.74%)
0.66EPS
3.19P/E
605.05MMarket Cap
Nov 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.27
1.28
Basic EPS, GAAP
-0.47
-0.49
-1
-2.27
-1.55
-1.15
-1.3
-1.61
-3.66
-2.9
-1.65
-0.88
0.59
0.67
Free Cash Flow per Basic Share
-0.54
0.36
-1.86
-2.02
-1.05
-1.32
-1.38
-1.54
-3.46
-2.86
-1.69
-0.89
0.6
0.66
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.32
0.42
1.38
1.13
4.36
1.95
1.63
7.41
4.42
2.33
0.92
0.63
1.07
0.94
Tangible Book Value per Share
0.14
0.17
1.38
1.13
4.36
1.95
1.63
7.35
4.37
2.3
0.89
0.61
1.06
0.93
Basic Weighted Avg Shares
17
17
17
21
39
80
85
107
100
128
170
184
249
249
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
317
317
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
48.75
52.31
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
3
3
4
3
3
3
2
Net Income, GAAP
-8
-8
-17
-47
-60
-91
-111
-173
-367
-372
-280
-162
147
167
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46.41
52.75
Working Capital
1
1
22
27
243
152
135
882
524
377
159
110
263
262
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
4
24
30
246
155
142
892
533
390
169
116
266
264
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
80.64
104.59
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
79.07
117.11
Return on Common Equity (%)
-255.95
-231.58
-123.36
-176.52
-43.64
-45.45
-74.54
-33.47
-51.45
-80.62
-100.29
-113.42
76.91
113.48

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
249
249
282
Market Capitalization
1,040
1,016
605

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
293
265
305
Cash, Cash Equivalents & STI
282
258
222
Accounts Receivable, Net
5
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
33
43
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
120.12%
-5.26%
128.61%
Free Cash Flow
9.61%
-28.33%
-191.96%
Net Income, GAAP
18.75%
-28.94%
-190.92%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
309
8
317
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.24
-0.23
-0.21
-0.88
2025
-0.19
-0.16
1.07
-0.13
0.59
2026
-0.13
-0.13
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hilde Hermansen Steineger
Full Time Employees
22
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ideon Gateway Lund SN Sweden 223 63
IPO Date
Jan 19, 2015
Website
cantargia.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cantargia AB (publ) (CANTA.ST) is a biotechnology company focused on the research, development, and commercialization of antibody-based therapies for cancer and inflammatory diseases. The company develops proprietary antibody therapeutics targeting the IL1RAP protein, including its lead candidate CAN10, an antibody in clinical development for autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), non-infectious uveitis, and acute respiratory distress syndrome (ARDS); and CAN04 (nadunolimab), a first-in-class antibody for cancer indications including non-small cell lung cancer (NSCLC), pancreatic cancer, and triple-negative breast cancer, which is being evaluated in combination with chemotherapy or immune checkpoint inhibitors. Cantargia operates primarily in the biopharmaceutical sector, targeting patients with high unmet medical needs in oncology and autoimmunity, with clinical-stage programs conducted through partnerships and trials across Europe and the United States. Founded in 2007 and headquartered in Lund, Sweden, the company conducts its research and development activities from facilities in Lund and has expanded its geographic footprint through international clinical collaborations. In recent developments within the last two years, Cantargia reported positive interim data from the Phase IIb CANergy trial of CAN04 in combination with chemotherapy for pancreatic cancer in 2024, strengthening its oncology pipeline; entered a strategic manufacturing partnership with AGC Biologics for CAN10 production to support upcoming clinical trials announced in early 2025; secured additional funding through a rights issue in late 2024 raising approximately SEK 200 million to advance both CAN04 and CAN10 programs; and initiated patient dosing in the Phase I trial of CAN10 for autoimmune uveitis in mid-2025, marking a significant expansion into inflammatory indications.